Technology PDF Print E-mail

 

Our patented monoclonal antibodies target various physical structures common to tumors or infected cells as a means to selectively target therapy and diagnostics, while sparing normal, healthy cells. Our most advanced research focus is on the development of therapeutic antibodies that specifically target and act upon features of cancer and viral infections, including the blood vessels feeding tumors, distinctive features in the central core of tumors and cells that have been infected with viruses. By targeting these features associated with disease, our agents have the potential for enhanced efficacy and safety compared to conventional approaches.

 

Our Clinical-Stage Platform Technologies Include:

  • Bavituximab, a phosphatidylserine (PS)-targeting experimental immunotherapeutic treatment treatment for multiple cancers
  • Cotara®, tumor necrosis therapy (TNT) for glioblastoma multiforme
  • 124-I-PGN650, a radio-labeled antibody fragment being evaluated as a tumor imaging agent

.